Business Wire

Esri and WorldPop Partner to Bring Updated Demographic Data to Policy Makers

Share

The global population grew by almost two billion people during the last 20 years—nearly 30 percent. Such growth is not evenly distributed over time or across space: the extremes include Qatar growing by 400 percent and Lithuania losing 25 percent. And even within countries, the rate of growth varies. To support the need for up-to-date population data that reflects these shifts, WorldPop and Esri, the global leader in location intelligence, have partnered to include WorldPop's 1-km annual gridded demographic datasets in ArcGIS Living Atlas of the World. The data covers 241 countries, territories, and dependencies for the 2000–2020 period.

"These datasets are critical for measuring and monitoring the accompanying sociodemographic changes over time and properly informing and supporting environmental, health, and development applications at local, subnational, national, and regional levels," said Professor Andrew Tatem, Director of WorldPop at the University of Southampton. "In this context, comparable, multitemporal, and spatially explicit detailed population distribution datasets are a fundamental prerequisite for communicating the impacts of population growth."

ArcGIS Living Atlas of the World is Esri's evolving collection of ready-to-use and up-to-date authoritative content in the form of maps, apps, and data layers—all accessible via a web browser and most Esri products.

"Having the WorldPop 1-km gridded demographic datasets available as imagery layers in ArcGIS Living Atlas of the World provides unprecedented convenience to query and analyze population anywhere on Earth," said Charlie Frye, Esri chief cartographer. "That these datasets no longer need to be downloaded or preassembled prior to use will result in substantial time and cost savings for any organization needing to understand recent population changes."

Queries can include the entire 21-year history of population changes for any group, including births and five-year age cohorts. The results of these queries can be spatiotemporally analyzed using Esri's ArcGIS software to find patterns. Multitemporal datasets depict grid cell level spatial distribution of total population, age, and sex cohorts and population density.

"The age and sex gridded datasets provide invaluable information about the spatial and temporal distribution of specific demographic groups, such as children, seniors, and women of childbearing age, which are well-known to be more vulnerable than others, and thus should be explicitly considered in decision- and policy-making processes," said Dr. Alessandro Sorichetta, Associate Professor in Applied Geospatial Research at WorldPop.

The 1-km raster layers, curated by the WorldPop Spatial Data Infrastructure Team led by Dr Maksym Bondarenko, are available in ArcGIS Living Atlas of the World for population per grid cell, population density per grid cell, and population by age and sex per grid cell.

To learn more about ArcGIS Living Atlas of the World and other Esri population data layers, please visit go.esri.com/livingatlas.

About WorldPop

WorldPop, initiated in October 2013 at the University of Southampton, develops methods and applications to produce open and high-resolution geospatial datasets on population distribution, demographics, and dynamics, with a focus mainly on low- and middle-income countries, to support development, disaster-response, and health applications. WorldPop research activities are designed with full open access and operational application in mind, using transparent, fully documented and peer-reviewed methods, to produce easily updatable outputs with accompanying metadata and, where possible, measures of uncertainty. WorldPop's work contributes to and benefits from direct engagement with multiple national statistical offices, national and international agencies, universities, research centers, and large international humanitarian donors, producing rapid and strong impacts from its research. WorldPop's population datasets and analyses inform several regional and global flagship reports and are the default geospatial demographic datasets used by many governments, international organizations, UN agencies, and private companies around the World. To learn more, visit our website and/or follow us on Twitter.

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.

Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email: jpruchniewski@esri.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye